Each uncoated tablet contains
MECHANISM OF ACTION:
Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor that stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin-converting enzyme, other hormone receptors, or ion channels. Studies also suggest that Telmisartan is a partial agonist of PPARy, an established target for antidiabetic drugs. This suggests that Telmisartan can improve carbohydrate and lipid metabolism and control insulin resistance without causing the side effects associated with full PPARy activators.
Used alone or in combination with other classes of antihypertensive for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors)
Flatulence, Indigestion, Stomach pain, Nausea, Diarrhea, Swelling of hands and feet, irregular heartbeat.
When pregnancy is detected, Telmisartan should be discontinued as soon as possible as it may cause injury and even death to the developing fetus when used in pregnancy during the second and third trimesters of pregnancy.
As directed by the physician.
Store protected from light and moisture.
20X10 tablets in an Outer carton.